Form 4: ClearPoint Neuro Director Acquires Shares in Lieu of Fees
SEC Form 4 Filing
Director Timothy T. Richards acquired 938 shares of ClearPoint Neuro, Inc. common stock on April 1, 2025, as payment for director fees.
Summary
- On April 1, 2025, Timothy T. Richards, a director of ClearPoint Neuro, Inc., acquired 938 shares of common stock.
- The shares were issued at a price of $11.89 per share, equivalent to the closing price of the company's common stock on March 31, 2025.
- This acquisition was made as payment for fees owed to Richards under the company's Non-Employee Director Compensation Plan.
- Following the transaction, Richards directly owns 66,288 shares of ClearPoint Neuro, Inc.
- Richards has granted power of attorney to Joseph M. Burnett, Ellisa Cholapranee, Danilo D'Alessandro, Jeremy Stigall, and Mazin Sabra to handle SEC filings related to company securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The transaction reflects standard director compensation practices and insider alignment with company interests. There are no indications of negative news or concerns.
Positives
- The acquisition of shares by a director demonstrates continued investment and alignment with the company's interests.
Industry Context
Director compensation in the form of stock is a common practice to align the interests of directors with those of shareholders. This Form 4 filing is a routine disclosure required by the SEC.
Comparison to Industry Standards
- Stock-based compensation for directors is a common practice across the industry, with companies like Medtronic and Stryker also utilizing similar methods.
- The amount of stock granted to directors varies widely based on company size, performance, and compensation policies.
- ClearPoint Neuro's approach appears consistent with industry norms for companies of its size and stage of development.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders by aligning director interests with company performance.
Key Dates
| Date | Description |
|---|---|
| 01/15/2025 | Date of execution of the Power of Attorney. |
| 03/31/2025 | Closing price used to calculate share price for director compensation. |
| 04/01/2025 | Date of the transaction where Timothy T. Richards acquired shares. |
| 04/02/2025 | Date of the Form 4 filing. |
Keywords
ClearPoint Neuro, Director Compensation, Form 4, Share Acquisition, Timothy T. Richards, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.